Follow on our innovation
CIS Pharma at Congress of European Association of Nuclear Medicine, EANM, in Barcelona
Barcelona, Spain, Saturday, October 15, 2022 – CIS Pharma will attend the 35th Annual Congress of the European Association of Nuclear Medicine in Barcelona. The team is looking forward to learn more from world-leading [...]
Innosuisse grants further funding for the CIS Pharma radioligand program
Bubendorf, Switzerland, Tuesday, October 4, 2022 – Based on the successful developments in the radioligand program, CIS Pharma and the ETH Zürich were granted continued funding for their development collaboration. Significant progress was achieved with [...]
CIS Pharma at Sachs Biotech in Europe Forum in Basel
Basel, Switzerland, Wednesday, September 21, 2022 – CIS Pharma will attend the 22nd Annual Biotech in Europe Forum in Basel. Taking place during the Sachs Autumn Life Sciences Week, the team is looking forward [...]
CIS Pharma performing pre-clinical study with radioligand targeting CD 171 with Lutetium 177
Bubendorf, Switzerland, Tuesday, September 18 - CIS Pharma has initiated the production of an antibody-radionuclide conjugate, ARC, based on its humanized lead anti-CD171 antibody. The ARC Lutetium-177, at a radionuclide-to-antibody ratio, RAR, of four. Lutetium-177 [...]